Vaccines, Blood & Biologics
-
Zemaira
STN: 125078
Proper Name: Alpha1-Proteinase Inhibitor (Human)
Tradename: Zemaira
Manufacturer: Aventis Behring LLC, License #1281
Indication:
- Chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor deficiency and evidence of emphysema
-
Supporting Documents
July 8, 2003 Approval Letter - Zemaira
STN 125078/0, indicated for use as chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor deficiency and evidence of emphysema.Summary Basis for Regulatory Action - Zemaira (PDF - 1.9MB)
-
-
Related Information
FDA Online Label Repository
Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.
-
Contact FDA
(800) 835-4709
(301) 827-1800
Consumer Affairs Branch (CBER)
Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Food and Drug Administration
1401 Rockville Pike
Suite 200N/HFM-47
Rockville, MD 20852-1448
-
-